Cost Analysis of Therapy on Urinary Tract Infection Inpatients in Dr. Moewardi Hospital Surakarta on 2016
| Main Authors: | Astuti, Windi, Widodo, Gunawan Pamudji, Herowati, Rina |
|---|---|
| Format: | Article info application/pdf Journal |
| Bahasa: | ind |
| Terbitan: |
Fakultas Farmasi Universitas Setia Budi
, 2018
|
| Online Access: |
http://ejurnal.setiabudi.ac.id/ojs/index.php/farmasi-indonesia/article/view/353 http://ejurnal.setiabudi.ac.id/ojs/index.php/farmasi-indonesia/article/view/353/367 |
| ctrlnum |
article-353 |
|---|---|
| fullrecord |
<?xml version="1.0"?>
<dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><title lang="en-US">Cost Analysis of Therapy on Urinary Tract Infection Inpatients in Dr. Moewardi Hospital Surakarta on 2016</title><title lang="id-ID">Analisis Biaya Terapi pada Pasien Infeksi Saluran Kemih Rawat Inap di RSUD Dr. Moewardi Surakarta pada Tahun 2016</title><creator>Astuti, Windi</creator><creator>Widodo, Gunawan Pamudji</creator><creator>Herowati, Rina</creator><description lang="en-US">Urinary tract infection is one of the infectious diseases that occur due to the presenceof microorganisms in the urine. Urinary tract infection financing was regulated in the INA-CBG’srates. The study purpose was determined the conformity of real cost to the INA-CBG’s rates inhospitalized of national health insurance patients with urinary tract infection disease in Dr.Moewardi hospital Surakarta in 2016.This study was an observational study using a cross sectional design. Retrospectivedata collection method. Data were analyzed to see the treatment pattern of patients duringhospitalization, to find the difference in real costs with INA-CBG's rates using the one sample ttest,and to see factors related to real costs using the bivariate correlation test.The result showed that the treatment pattern for hospitalized patients with urinary tractinfection are using Ceftriaxone (40,8%), Cefixime (7,1%), Ceftazidime (10,2%), Ciprofloxacin(26,5%), Levofloxacin (9,2%), Amoxicillin (3,1%), Ampicillin (1,0%), and Gentamicin (2,0%). Theanalysis of real cost to the INA-CBG’s rates showed the differences between real cost and INACBG’srate of national health insurance patients with urinary tract infection disease.This difference shows a positive condition, where the total real costs are lower than the INACBG'srates. The factor related to the real cost of urinary tract infection treatment including ofLOS, secondary diagnoses, and treatment classes.</description><description lang="id-ID">Infeksi saluran kemih adalah salah satu penyakit infeksi yang terjadi akibat adanyamikroorganisme dalam urin. Infeksi saluran kemih pembiayaannya diatur dalam tarif INA-CBG’s.Tujuan penelitian ini untuk mengetahui kesesuaian biaya riil dengan tarif INA-CBG’s padapasien JKN rawat inap penyakit infeksi saluran kemih di RSUD Dr. Moewardi Surakarta tahun2016.Penelitian ini merupakan observasional dengan menggunakan rancangan penelitiancross sectional. Metode pengambilan data secara retrospektif. Data dianalisis untuk melihatpola pengobatan pasien selama menjalani rawat inap, untuk mencari selisih biaya riil dengantarif INA-CBG’s menggunakan uji one sample t-test, dan untuk melihat faktor yang berhubungandengan biaya riil menggunakan uji korelasi bivariat.Hasil penelitian menunjukkan pola pengobatan pasien infeksi saluran kemihmenggunakan antibiotik Ceftriaxone (40,8%), Cefixime (7,1%), Ceftazidime (10,2%),Ciprofloxacin (26,5%), Levofloxacin (9,2%), Amoxicillin (3,1%), Ampicillin (1,0%), danGentamicin (2,0%). Analisis biaya rill dengan tarif INA-CBG’s terdapat perbedaan antara biayariil dengan tarif INA-CBG’s pada pasien JKN rawat inap penyakit infeksi saluran kemih.Perbedaan ini menunjukkan selisih yang positif, dimana total biaya riil lebih rendahdibandingkan tarif INA-CBG’s. Faktor yang behubungan dengan biaya riil pengobatan infeksisaluran kemih adalah LOS (Length of Stay), diagnosa sekunder, dan tingkat keparahan.</description><publisher lang="en-US">Fakultas Farmasi Universitas Setia Budi</publisher><date>2018-04-30</date><type>Journal:Article</type><type>Other:info:eu-repo/semantics/publishedVersion</type><type>Journal:Article</type><type>File:application/pdf</type><identifier>http://ejurnal.setiabudi.ac.id/ojs/index.php/farmasi-indonesia/article/view/353</identifier><identifier>10.31001/jfi.v15i1.353</identifier><source lang="en-US">Jurnal Farmasi Indonesia; Vol 15 No 1 (2018): Jurnal Farmasi Indonesia; 40-49</source><source lang="id-ID">Jurnal Farmasi Indonesia; Vol 15 No 1 (2018): Jurnal Farmasi Indonesia; 40-49</source><source>2302-4291</source><source>1693-8615</source><source>10.31001/jfi.v15i1</source><language>ind</language><relation>http://ejurnal.setiabudi.ac.id/ojs/index.php/farmasi-indonesia/article/view/353/367</relation><rights lang="en-US">Copyright (c) 2018 Jurnal Farmasi Indonesia</rights><recordID>article-353</recordID></dc>
|
| language |
ind |
| format |
Journal:Article Journal Other:info:eu-repo/semantics/publishedVersion Other File:application/pdf File Journal:Journal |
| author |
Astuti, Windi Widodo, Gunawan Pamudji Herowati, Rina |
| title |
Cost Analysis of Therapy on Urinary Tract Infection Inpatients in Dr. Moewardi Hospital Surakarta on 2016 |
| publisher |
Fakultas Farmasi Universitas Setia Budi |
| publishDate |
2018 |
| url |
http://ejurnal.setiabudi.ac.id/ojs/index.php/farmasi-indonesia/article/view/353 http://ejurnal.setiabudi.ac.id/ojs/index.php/farmasi-indonesia/article/view/353/367 |
| contents |
Urinary tract infection is one of the infectious diseases that occur due to the presenceof microorganisms in the urine. Urinary tract infection financing was regulated in the INA-CBG’srates. The study purpose was determined the conformity of real cost to the INA-CBG’s rates inhospitalized of national health insurance patients with urinary tract infection disease in Dr.Moewardi hospital Surakarta in 2016.This study was an observational study using a cross sectional design. Retrospectivedata collection method. Data were analyzed to see the treatment pattern of patients duringhospitalization, to find the difference in real costs with INA-CBG's rates using the one sample ttest,and to see factors related to real costs using the bivariate correlation test.The result showed that the treatment pattern for hospitalized patients with urinary tractinfection are using Ceftriaxone (40,8%), Cefixime (7,1%), Ceftazidime (10,2%), Ciprofloxacin(26,5%), Levofloxacin (9,2%), Amoxicillin (3,1%), Ampicillin (1,0%), and Gentamicin (2,0%). Theanalysis of real cost to the INA-CBG’s rates showed the differences between real cost and INACBG’srate of national health insurance patients with urinary tract infection disease.This difference shows a positive condition, where the total real costs are lower than the INACBG'srates. The factor related to the real cost of urinary tract infection treatment including ofLOS, secondary diagnoses, and treatment classes. Infeksi saluran kemih adalah salah satu penyakit infeksi yang terjadi akibat adanyamikroorganisme dalam urin. Infeksi saluran kemih pembiayaannya diatur dalam tarif INA-CBG’s.Tujuan penelitian ini untuk mengetahui kesesuaian biaya riil dengan tarif INA-CBG’s padapasien JKN rawat inap penyakit infeksi saluran kemih di RSUD Dr. Moewardi Surakarta tahun2016.Penelitian ini merupakan observasional dengan menggunakan rancangan penelitiancross sectional. Metode pengambilan data secara retrospektif. Data dianalisis untuk melihatpola pengobatan pasien selama menjalani rawat inap, untuk mencari selisih biaya riil dengantarif INA-CBG’s menggunakan uji one sample t-test, dan untuk melihat faktor yang berhubungandengan biaya riil menggunakan uji korelasi bivariat.Hasil penelitian menunjukkan pola pengobatan pasien infeksi saluran kemihmenggunakan antibiotik Ceftriaxone (40,8%), Cefixime (7,1%), Ceftazidime (10,2%),Ciprofloxacin (26,5%), Levofloxacin (9,2%), Amoxicillin (3,1%), Ampicillin (1,0%), danGentamicin (2,0%). Analisis biaya rill dengan tarif INA-CBG’s terdapat perbedaan antara biayariil dengan tarif INA-CBG’s pada pasien JKN rawat inap penyakit infeksi saluran kemih.Perbedaan ini menunjukkan selisih yang positif, dimana total biaya riil lebih rendahdibandingkan tarif INA-CBG’s. Faktor yang behubungan dengan biaya riil pengobatan infeksisaluran kemih adalah LOS (Length of Stay), diagnosa sekunder, dan tingkat keparahan. |
| id |
IOS8181.article-353 |
| institution |
Universitas Setia Budi Surakarta |
| institution_id |
2291 |
| institution_type |
library:university library |
| library |
Fakultas Farmasi |
| library_id |
2932 |
| collection |
Jurnal Farmasi Indonesia |
| repository_id |
8181 |
| subject_area |
Pharmacology and Therapeutics/Farmakologi dan Terapi Farmakologi chemical Pharmacy Practical Pharmacy/Farmasi Praktis natural medicine |
| city |
KOTA SURAKARTA |
| province |
JAWA TENGAH |
| repoId |
IOS8181 |
| first_indexed |
2019-09-30T10:19:40Z |
| last_indexed |
2020-09-28T15:06:52Z |
| recordtype |
dc |
| _version_ |
1686610695261519872 |
| score |
17.607244 |